STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCKT
  4. [8-K] Rocket Pharmaceuticals, Inc. Reports Material Event

[8-K] Rocket Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RCKT logo
Rocket Pharmaceu

NASDAQ:RCKT

RCKT Rankings

#3666 Ranked by Market Cap
N/A Ranked by Dividends

RCKT Latest News

Jul 17, 2025
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
Jun 30, 2025
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
May 27, 2025
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
May 15, 2025
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy
May 9, 2025
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

RCKT Latest SEC Filings

Jul 18, 2025
[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity

RCKT Stock Data

340.45M
103.72M
3.02%
106.9%
10.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK